Psoriasis is an immune-mediated chronic, systemic, and inflammatory disease, with its core pathogenesis pathway regulated by the Janus kinase (JAK) family mediated JAK-STAT pathway.

1、 Drug name

1. Common name: Deucravatinib

2. Product Name: SOTYKTU ™

2、 Indications

1. Used to treat adult patients with moderate to severe plaque psoriasis who are suitable for systemic therapy or phototherapy.

2. Restricted use: It is not recommended to use it in combination with other potent immunosuppressants.

3、 Specifications and characteristics

6mg、 tablet

4、 Main components

1. Each tablet contains 6mg of deuterated celecoxib.

2. Accessories include: anhydrous lactose, cross-linked carboxymethyl cellulose sodium, hydroxypropyl methyl cellulose acetate succinate, magnesium stearate, microcrystalline cellulose, and silica.

5、 Usage and dosage

1. The recommended dosage is 6mg orally once daily, which can be taken with food or on an empty stomach.

2. It should be swallowed whole and should not be crushed, cut or chewed.

3. If one dose is missed, there is no need to supplement it, and the next dose should be taken according to the original plan.

6、 Dose adjustment

1. Mild to moderate liver dysfunction (Child Pugh A or B grade) patients do not require dose adjustment.

2. Not recommended for patients with severe liver dysfunction (Child Pugh C grade).

3. Patients with renal insufficiency (including end-stage renal disease requiring dialysis) do not need to adjust their dosage.

7、 Medication precautions

1. Medication time: Take medication at a fixed time every day, unaffected by food.

2. Swallowing requirements: Swallow the entire tablet without damaging its structure.

3. Omission treatment: Do not supplement medication, continue taking medication according to the original plan.

4. Before treatment, tuberculosis screening, vaccination evaluation and liver function examination should be carried out.

5. Avoid using live vaccines simultaneously.

6. If symptoms such as infection, muscle pain, and allergic reactions occur during treatment, seek medical attention promptly.

8、 Medication for special populations

1. Pregnant women: There is insufficient data available, and animal experiments have not shown embryotoxicity, but caution should be exercised when using it.

2. Breastfeeding women: Medications may be secreted with breast milk and are not recommended for use during lactation.

3. Children: Safety and efficacy have not yet been established.

4. Elderly people (≥ 65 years old): have a higher risk of infection and serious adverse reactions, and need to be closely monitored.

5. Liver dysfunction: It is contraindicated for severe patients, and dose adjustment is not necessary for mild to moderate cases.

6. Renal insufficiency: No need to adjust dosage, including dialysis patients.

9、 Adverse reactions

Common adverse reactions (incidence ≥ 1%) include:

1. Upper respiratory tract infection

2. Elevated levels of creatine phosphokinase (CPK) in blood

3. Herpesvirus infection (such as herpes simplex)

4. Oral ulcer

5. Folliculitis

6. Acne vulgaris

Serious adverse reactions include:

1. Severe allergic reactions (such as angioedema)

2. Infection (such as pneumonia, COVID-19, tuberculosis)

3. Malignant tumors (including lymphoma)

4. Rhabdomyolysis

5. Elevated liver enzymes

6. Elevated blood lipids (triglycerides)

10、 Contraindications

It is contraindicated for individuals allergic to deuteroxenib or any excipients.

11、 Drug interactions

1. Avoid using live vaccines simultaneously.

2. No significant interactions were found when used in combination with drugs such as cyclosporine, fluvoxamine, ritonavir, difluorouracil, pyrimethamine, famotidine, or rabeprazole.

3. There was no clinically relevant effect observed when combined with rosuvastatin, methotrexate, mycophenolate mofetil, or oral contraceptives.

12、 Storage method

1. Store in an environment of 20 ° C to 25 ° C (68 ° F to 77 ° F), with short-term storage allowed at 15 ° C to 30 ° C (59 ° F to 86 ° F).

2. Keep the medicine intact and avoid moisture, high temperature, and light exposure.

Deucravacitinibinformation